Finance

Lists
Q2 2026 earnings • released • EPS miss -35.17% • Revenue beat +7.36%
See results
VIR:NASDAQ
Vir Biotechnology Inc
$8.82
+0.63%
(+0.055) 1D
$8.85
+0.34% (+0.030)
After hours
Closed: Aug 7, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for VIR...
Open
$8.87
High
$9.03
Low
$8.75
Mkt. cap
1.49B
Avg. vol.
1.80M
Volume
1.66M
52-wk high
$11.66
52-wk low
$4.16
EPS
-$3.14
Beta
1.66
Shares outstanding
169.22M
No. of employees
367
Open
$8.87
High
$9.03
Low
$8.75
Mkt. cap
1.49B
Avg. vol.
1.80M
Volume
1.66M
52-wk high
$11.66
52-wk low
$4.16
EPS
-$3.14
Beta
1.66
Shares outstanding
169.22M
No. of employees
367
News stories
From sources across the web
About Vir Biotechnology Inc
CEOMarianne De Backer
Employees367
FoundedApr 7, 2016
HeadquartersSan Francisco, California, United States
SectorBiotechnology
Websitevir.bio
Analyst ratings
Based on 8 analysts giving stock ratings to VIR in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for VIR in the last 3 months.
Highest
Current $8.82
$30.00 (+240.14%)
Average
$21.29 (+141.38%)
Lowest
$15.00 (+70.07%)
Analyst
Recommendation
Action
Price target
Projected
Date
Alec Stranahan
Bank of America Securities
Buy
Reiterated
$15.00
+70.1%
08/07/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
$22.00
+149.4%
08/06/2026
Joseph Stringer
Needham
Buy
Reiterated
$18.00
+104.1%
08/06/2026
Michael Ulz
Morgan Stanley
Buy
Reiterated
$25.00
+183.4%
08/06/2026
Roanna Ruiz
Leerink Partners
Buy
Maintained
$19.00
+115.4%
08/06/2026
Phil Nadeau
TD Cowen
Buy
Maintained
-
-
08/05/2026
Etzer Darout
Barclays
Buy
Maintained
$30.00
+240.1%
08/06/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$20.00
+126.8%
06/03/2026
Paul Choi
Goldman Sachs
Buy
Maintained
$21.00
+138.1%
05/06/2026
Sean McCutcheon
Raymond James
Buy
Maintained
$19.00
+115.4%
02/24/2026
Last report
Aug 5, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$0.47 / $0.72
-35.17%miss
Revenue / Est. (USD)
238.95M / 222.57M
+7.36%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
240.00K
64.07M
-29.00K
238.95M
Cost of goods sold
151.45M
88.46M
109.81M
-
Cost of revenue
151.45M
88.46M
109.81M
-
Research and development expenses
-
-
-
135.28M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
22.23M
23.62M
23.34M
30.20M
Operating expense
22.23M
23.62M
23.34M
165.48M
Total operating expenses
173.68M
112.07M
133.15M
165.48M
Operating income
-173.44M
-48.00M
-133.18M
73.47M
Other non operating income
-228.00K
-335.00K
-254.00K
-451.00K
EBT including unusual items
-162.97M
-43.06M
-125.52M
80.26M
EBT excluding unusual items
-164.31M
-40.53M
-126.24M
81.98M
Income tax expense
168.00K
-137.00K
170.00K
179.00K
Effective tax rate
-0.10%
0.32%
-0.14%
0.22%
Other operating expenses
-
-
-
-
Net income
-163.14M
-42.92M
-125.70M
80.08M
Net profit margin
-67,975.42%
-66.99%
433,431.03%
33.51%
Earnings per share
-1.17
-0.31
-0.85
0.47
Interest and investment income
9.36M
7.80M
7.19M
8.97M
Interest expense
-
-
-
-
Net interest expenses
9.36M
7.80M
7.19M
8.97M
Depreciation and amortization charges
-
-
-
-
EBITDA
-170.44M
-45.10M
-130.37M
76.27M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps